Evolution of Medicine Has Produced Novel New Treatments

Therapeutic interventions have evolved from people taking a pill every day to treat a condition to the one-time cell and gene therapies aimed at halting disease progression or even curing a disease. The rise of these innovative new products means that payers need more information than ever in order to properly assess treatments, as well as updated reimbursement models.

“The science is moving at lightning speed, and what we thought was previously impossible has now become a reality with some of the newer gene therapies and other novel drug approvals,” observes Reta Mourad, Pharm.D., a senior director on the access experience team at PRECISIONvalue. “As we learn more about diseases and develop a deeper understanding down to the genetic and molecular level, we are able to see advances in therapies that were unheard of,” for example with chimeric antigen receptor T cell (CAR-T) therapies, the first of which were approved in 2017.

Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

a-businessman-touching-screen
May 12

Do Pharma/PBM Contracts Play Role in Drugmakers’ Revenue Leakage?

READ MORE
a-doctor-speaking-to-a-patient
May 12

Novartis’ Pluvicto Brings New Mechanism of Action to mCRPC Options

READ MORE
an-elderly-looking-outside
May 12

Study Finds PBC Drug’s Real-World, Trial Side Effects Are Similar

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today